Zentalis Pharmaceuticals, Inc. Deconsolidation, Gain (Loss), Amount
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Deconsolidation, Gain (Loss), Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Other Income
us-gaap:DeconsolidationGainOrLossAmount · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for the quarter ending 2025-12-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for the quarter ending 2025-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for the quarter ending 2025-06-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for fiscal 2024 was $79.00K.
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for fiscal 2023 was $0.00.
- Zentalis Pharmaceuticals, Inc. deconsolidation, gain (loss), amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Deconsolidation, Gain (Loss), Amount 3 month | Deconsolidation, Gain (Loss), Amount 6 month | Deconsolidation, Gain (Loss), Amount 9 month | Deconsolidation, Gain (Loss), Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $79.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $79.00K 10-Q · filed 2025-11-10 | $79.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $79.00K 10-Q · filed 2025-08-06 | $79.00K derived: sum of 3 quarters · filed 2026-03-26 | $79.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $79.00K 10-Q · filed 2025-05-14 | $79.00K derived: sum of 2 quarters · filed 2026-03-26 | $79.00K derived: sum of 3 quarters · filed 2026-03-26 | $79.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 3 quarters · filed 2025-03-26 | $0.00 derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-26 | $0.00 derived: sum of 3 quarters · filed 2025-03-26 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $0.00 derived: sum of 2 quarters · filed 2025-03-26 | $0.00 10-K · filed 2025-03-26 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | $51.58M derived: sum of 2 quarters · filed 2022-11-09 | $51.58M derived: sum of 3 quarters · filed 2022-11-09 | $51.58M 10-K · filed 2024-02-27 |
| 2021-09-30 | $51.58M 10-Q · filed 2022-11-09 | $51.58M derived: sum of 2 quarters · filed 2022-11-09 | $51.58M 10-Q · filed 2022-11-09 | $51.58M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $0.00 10-K · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $0.00 10-K · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |